Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification

Kim, K; Kim, W.S; Jung, Chul Won; Im, Young‐Hyuck; Kang, Wonseok; Lee, M.H; Park, C.H; Ko, Young Hyeh; Ree, H. J.; Park, K

doi:10.1016/s0959-8049(01)00344-6

Cited by 62 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is in keeping with other smaller studies [5][6][7]12,[18][19][20][21][22][23] in which PTCL-NOS was usually the most frequent subtype, composing 17% to 59% of all cases. To date, our study is one of the largest reported series of PTCL-NOS.…”

Section: Discussionsupporting

confidence: 92%

“…Most of our patients (87%) presented with nodal disease, but extranodal disease was also present in 49% of these patients, whereas only 13% presented with extranodal disease only. As in other studies, [5][6][7][8][9][10][11][12][13][20][21][22][23]28 the majority of our patients (80%) were treated with combination chemotherapy including an anthracycline, but the complete remission rate was low (56%) and there were few cures, with no survival advantage for those receiving an anthracycline. The 5-year OS (32%) and FFS (20%) of the patients in our series were poor, but in keeping with the survival reported in other studies.…”

supporting

confidence: 68%

“…The 5-year OS (32%) and FFS (20%) of the patients in our series were poor, but in keeping with the survival reported in other studies. [5][6][7][8][9][10][11][12][13][20][21][22][23]28 The use of more intensified chemotherapy in patients with PTCL-NOS does not appear to be beneficial, 7,11 although one study reported improved survival. 12 Therefore, new treatment regimens are clearly needed for PTCL-NOS, including the addition of novel agents to existing regimens, new regimens combining novel agents, use of monoclonal antibodies, and innovative strategies for stem cell transplantation.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger

Savage

Harris

et al. 2011

Blood

383

369

View full text Add to dashboard Cite

The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted clinical and pathologic material on 1314 cases. One objective was toanalyze the clinical and pathologic features of 340 cases of PTCL, not otherwise specified. The median age of the patients was 60 years, and the majority (69%) presented with advanced stage disease. Most patients (87%) presented with nodal disease, but extranodal disease was present in 62%. The 5-year overall survival was 32%, and the 5-year failure-free survival was only 20%. The majority of patients (80%) were treated with combination chemotherapy that included an anthracycline, but there was no survival advantage. The International Prognostic Index (IPI) was predictive of both overall survival and failure-free survival (P < .001). Multivariate analysis of clinical and pathologic prognostic factors, respectively, when controlling for the IPI, identified bulky disease (> 10 cm), thrombocytopenia (< 150 ؋ 10 9 /L), and a high number of transformed tumor cells (> 70%) as adverse predictors of survival, but only the latter was significant in final analysis. Thus, the IPI and a single pathologic feature could be used to stratify patients with PTCL-not otherwise specified for novel and risk-adapted therapies. (Blood. 2011;117(12):3402-3408) IntroductionPeripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are an uncommon and heterogeneous group of disorders that compose 5% to 20% of all non-Hodgkin lymphomas (NHLs) in different parts of the world. 1,2 In recent years, the incidence of PTCL and NKTCL in the United States has increased by almost 3-fold with an annual increase of 3.8%, whereas the incidence of B-cell lymphoma and Hodgkin lymphoma has been relatively stable. 3,4 One of the most common subtypes of PTCL is a heterogeneous group of nodal and extranodal mature T-cell lymphomas that do not correspond to any of the specifically defined T-cell entities in the World Health Organization classification, 1 and are therefore called PTCL, not otherwise specified (NOS). Uncommon variants of PTCL-NOS include lymphoepithelioid (Lennert) lymphoma, and cases with a follicular or T-zone pattern of growth. 1 Over the last 12 years, several clinical studies have attempted to identify the clinical and pathologic features of prognostic importance in PTCL-NOS, but the number of cases in these studies was generally small and the findings have been inconsistent or unconfirmed. [5][6][7][8][9][10][11][12][13] The International Peripheral T-cell Lymphoma Project was undertaken as a large retrospective study of PTCL and NKTCL in North America, Europe, and Asia with the goal of better characterizing this group of NHL. One objective of was to analyze the clinical and pathologic features of the 340 cases of PTCL-NOS in the study, and to determine the important prognostic factors for this uncommon entity. MethodsTwenty-two institutions in North America, Europe, and Asia partici...

show abstract

Section: Discussionsupporting

confidence: 92%

supporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger

Savage

Harris

et al. 2011

Blood

383

369

View full text Add to dashboard Cite

show abstract

“…The incidence of patients with lymphoma is as high as 11% in China (3). NK/T-cell lymphomas usually occur in middle-aged patients, and their features are characterized by localized disease in approximately two-thirds of patients, along with frequent adjacent tissue invasion, a high frequency of 'B' symptoms, despite apparently limited disease, and rare bone marrow involvement (4)(5)(6). In addition, ENKTL is highly invasive, resistant to conventional chemotherapy, highly malignant, associated with short survival time and rapid clinical progression, and has a relatively poor prognosis (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma

Yuan

Wei

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to compare the efficacy of an L-asparaginase-based regimen and a CHOP regimen followed by radiotherapy as first-line treatments for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma (ENKTL). A total of 69 patients received the CHOP regimen as the first-line treatment and 112 patients received the L-asparaginase-based regimen. All patients received radical radiotherapy following two cycles of chemotherapy. The overall response rates of the L-asparaginase-based and CHOP treatment groups were 90.18 and 72.46%, respectively (P=0.002). The one, two, and five-year overall survival (OS) rates and progression-free survival (PFS) rates of the L-asparaginase group were 96.0, 88.3, 65.1, 94.2, 79.8 and 50.0%, respectively. The one, two, and five-year OS and PFS rates of the CHOP group were 82.6, 61.9, 25.8, 63.8, 44.0 and 21.0%, respectively (P<0.001). Compared with CHOP treatment, L-asparaginase-based chemotherapy combined with radiotherapy was a safe and highly effective treatment for newly diagnosed ENKTL.

show abstract

“…However, the clinical outcome is poor with this therapy except for anaplastic large-cell lymphoma (ALCL), ALK positive type [2]. Large prospective series did indicate a higher relapse rate and a poorer survival for PTCL than DLBCL [2,[5][6][7][8][9][10][11][12][13]. Various chemotherapy regimens have been tried out--such as MegaCHOP (intensive or higher dose of CHOP) with or without etoposide [14,15], epirubicin substituted for doxorubicin and addition of bleomycin (CEOP-B) [16], CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone) [17], CHOP or MegaCHOP/ESHAP (etoposide, cisplatin, cytarabine and prednisone) [18,19] and VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP); doxorubicin, ranimustine, and prednisone (AMP); vindesine, etoposide, carboplatin, and prednisone (VECP)) [20]; fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high doses of methotrexate and cytarabine (hyperCVAD) [21,22]--with no superior efficacy to CHOP except CMED at the expense of higher treatment toxicity.…”

Section: Introductionmentioning

confidence: 99%

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Kuan

Chang

Lau

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18-60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell and NK/T-cell neoplasms (n PTCL = 6, n T-cell ALL = 3, n NK/T-cell neoplasms = 4) from 2006 to 2008 were treated with alemtuzumab-hyperCVAD regimen. A total of nine patients (69%) responded to the regimen, with seven achieved complete remission and two achieved partial remission. The median progression free survival and overall survival duration among the responders with complete remission were 12.9 and 24.9 months respectively. The incidence of relapse among the responders was 44% and the overall survival rate was 23%. Only four (31%) patients completed the six cycles of alemtuzumab-hyperCVAD. Others were stopped earlier due to progressive disease (n = 2), cytomegalovirus (CMV) reactivation and/or disease (n = 3), death not due to disease (n = 2), and patient's refusal to continue alemtuzumab (n = 2). The incidence of death not due to disease, CMV reactivation and recurrent CMV reactivation were 50, 50 and 17%, respectively. This study shows that alemtuzumab in combination with hyperCVAD regimen is a feasible regimen but with high toxicity. The toxicity might be reduced with the incorporation of filgrastim and use of valganciclovir as CMV prophylaxis.

show abstract

Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification

Cited by 62 publications

References 19 publications

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Contact Info

Product

Resources

About